CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities:
Net loss	$ (35,952)	$ (243,569)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	19,791	9,089
Impairment of intangible assets	0	77,358
Provision for bad debt expense	230	(12)
Amortization of premium/discount on purchased securities	42	(51)
Write-down of inventory	616	4,836
(Gain)/loss on disposal of property & equipment	230	0
Non-cash equity-based compensation expense	5,879	9,407
Non-cash IPR&D expense	0	18,029
Amortization of debt discount and debt issuance costs	8,103	7,513
Gains on marketable securities, net	(10)	(270)
Change in fair value of contingent consideration	0	(21)
Deferred income taxes	630	630
Non-cash lease expense	1,279	0
Gain on sale of assets	(15,853)	0
Changes in operating assets and liabilities:
Accounts receivable, net	28,828	(7,825)
Inventories	(872)	(3,323)
Prepaid and other current assets	(1,790)	(5,562)
Accounts payable and accrued expenses	(54,216)	36,137
Deferred revenues	0	(101)
Other assets and liabilities	(377)	1,283
Net cash used in operating activities	(43,442)	(96,452)
Cash flows from investing activities:
Proceeds from sales or maturities of marketable securities	33,735	46,420
Purchase of marketable securities	(23,345)	(14,815)
Net proceeds from the sale of assets	19,344	0
Capital expenditures	(68)	(1,907)
Net cash provided by investing activities	29,666	29,698
Cash flows from financing activities:
Payments to settle convertible notes	0	(21,417)
Payments of contingent consideration	(17)	(27)
Payments for repurchases of common stock	0	(13,730)
Proceeds from the issuance of common stock under the ESPP	631	851
Proceeds from the exercise of common stock options	0	30
Payments of employee tax withholding related to equity-based compensation	(1,326)	(1,748)
Net cash used in financing activities	(712)	(36,041)
Net decrease in cash, cash equivalents, and restricted cash	(14,488)	(102,795)
Cash, cash equivalents, and restricted cash at beginning of the period	113,504	253,751
Cash, cash equivalents, and restricted cash at end of the period	99,016	150,956
Supplemental data for cash flow information:
Cash (refunded) paid for taxes	(256)	433
Cash paid for interest	5,200	5,467
Non-cash investing and financing activities:
Milestone payment accrued for FDA approval of Vyleesi	0	60,000
Settlement of note receivable in connection with Perosphere acquisition	0	10,000
Right-of-use assets obtained in exchange for lease liabilities	$ 0	$ 918